Marc N. Casper, Chairman and Chief Executive Officer of Thermo Fisher Scientific Inc. (NYSE: TMO), filed a Form 4 on August 10, 2026, reporting multiple common stock transactions executed on August 7, 2026, including an option exercise and a series of open-market sales under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Casper acquired 275 shares of common stock on August 7, 2026, via exercise of a stock option at $309.63 per share.
  • Direct share sales: Casper disposed of shares directly across multiple transactions on August 7, 2026, at prices ranging from $577.37 to $593.36 per share, with the final reported direct holding standing at 123,925.358 shares.
  • Indirect sales completed: All shares held indirectly through Floral Park Associates, Inc. were sold in multiple transactions, reducing that position to 0 shares.
  • Trading plan: All sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Casper on April 27, 2026.
  • Remaining indirect holdings: Following the transactions, Casper retained 5,000 shares indirectly through MNC 2020 Irrevocable Trust and 11,300 shares indirectly through Alison Casper 2020 Irrevocable Trust.
  • Stock options: Following the exercise, Casper held 20,275 stock options with an exercise price of $309.63 and an expiration date of February 25, 2027.

Details of Casper's August 7, 2026 Transactions in Thermo Fisher Scientific Shares

According to the filing, Casper first exercised a stock option (transaction code M) to acquire 275 shares of Thermo Fisher Scientific common stock at an exercise price of $309.63 per share. Thermo Fisher Scientific is a life sciences company whose common stock trades on the New York Stock Exchange under the ticker TMO. The option had vested in four equal installments on February 25 of each year from 2021 through 2024, as disclosed in the filing's footnotes.

Following the exercise, the filing reports that Casper sold shares directly in a series of transactions (transaction code S), with individual lot sizes ranging from 2 to 63 shares and weighted average sale prices spanning from $577.37 to $593.36 per share. Several prices listed are weighted averages, and the filing states that Casper undertakes to provide full information on the number of shares sold at each separate price within the reported ranges upon request by Thermo Fisher Scientific, any TMO security holder, or the SEC staff. After all direct sales, the filing reports Casper's direct beneficial ownership at 123,925.358 shares of common stock.

Separately, shares held indirectly through Floral Park Associates, Inc. were also sold across multiple transactions on August 7, 2026, at prices ranging from $577.37 to $593.36 per share, reducing that indirect holding from an opening balance to 0. The filing notes that Casper disclaims beneficial ownership of shares held through MNC 2020 Irrevocable Trust and Alison Casper 2020 Irrevocable Trust, "except to the extent of any pecuniary interest therein." Those two trusts held 5,000 and 11,300 shares, respectively, and were not subject to any reported transactions in this filing.

What Was Disclosed

The Form 4 filed August 10, 2026, reports that Thermo Fisher Scientific Chairman and CEO Marc N. Casper exercised stock options and sold common stock directly and indirectly on August 7, 2026, under a Rule 10b5-1 plan adopted April 27, 2026.